Innovate UK

Z-PULSE, a spin-off from the University of Surrey, creates wearable health sensors that run on their own power.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Esox Biologics provides innovative and sustainable solutions for aquatic veterinary medicine. The company offers a disease prediction platform called eForesee, which uses data-driven predictions unique to individual farms. Regular monitoring of the aquatic environment and livestock health is a key component of their services. Esox Biologics utilizes extensive knowledge of the aquatic microbiome to prevent the spread of infectious diseases among aquatic animals by collecting environmental DNA and employing next-generation sequencing technologies.

Axial3D specializes in 3D printing for healthcare, focusing on creating precise, patient-specific physical models derived from CT and MRI scans. Their online ordering portal enables secure uploads, with an expert team using advanced technology to deliver these models directly to consultants. The company aims to enhance surgical planning, technique development, and ultimately improve patient outcomes by integrating 3D printing into mainstream medical practice.

ChromaTwist is a developer of innovative ultraviolet fluorescent dyes designed for applications in bio-sensing and bio-imaging diagnostic tests. The company's proprietary technology platform utilizes shifted organic fluorescent dyes, which emit visible light upon UV irradiation. These dyes are composed of aromatic organic materials featuring donor and acceptor groups, allowing them to absorb UV light and emit across the full visible spectrum. ChromaTwist's modular and scalable chemistry enables the continuous advancement of their fluorophores, thereby expanding their potential applications in the healthcare sector, particularly in areas like flow cytometry and multiphoton microscopy.

LaennecAI is a clinical AI company specializing in chronic disease management solutions. It has developed a medical device, a digital stethoscope, which transforms modern smartphones into powerful diagnostic tools. The company's technology enables precise monitoring and analysis of respiratory and cardiac sounds, facilitating telemedicine, remote patient monitoring, and virtual wards. This ensures patients receive in-depth, reliable analysis and continuous care.

The goal of Reneural is to use technology to revolutionize healthcare delivery by increasing its effectiveness, efficiency, and accessibility for both patients and physicians.

Myogenes provides psychiatric tests, heredity cancer tests, and mental health mind maps.

Biovit is a company that specializes in the development of fortified foods. It uses 100% organic plant extracts, naturally rich in vitamins and minerals, to enhance the nutritional value of its products. The company aims to address health and environmental issues such as obesity and malnutrition, while also reducing food waste. Biovit has clinically developed and tested organic micronutrient blends for use in various food and beverage products, as well as supplements, providing consumers with organically sourced, nutrient-dense options.

Naitive is a population health company focused on transforming patient care through the development of AI-enabled clinical pathways. It specializes in creating medical device technology aimed at preventing chronic diseases. The company's software leverages artificial intelligence, clinical data, and digital interventions to enhance the detection, treatment, and management of chronic conditions. By utilizing scalable computational capabilities, Naitive's solutions enable clinicians to improve care coordination while reducing costs, time, and the likelihood of treatment failures.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

Fuse Diagnostics is a company dedicated to providing lab-quality diagnostic information through innovative and cost-effective testing solutions. The company manufactures diagnostic products designed to deliver accurate results for various applications, including food and water testing, bioprocessing industry needs, and cell biology research. Fuse Diagnostics aims to make high-quality diagnostic information accessible wherever it is needed, offering low-cost test kits with integrated readout technology that provide rapid results.

Presymptom Health is a medical technology company dedicated to advancing healthcare through the development of pre-symptomatic diagnostic tests and clinical decision support algorithms. The company focuses on creating innovative blood tests designed to detect illnesses at an early stage, particularly aiming to predict the onset of sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health seeks to improve critical care outcomes and enhance patient management, ultimately contributing to better survival rates and healthcare efficiency.

Cortirio is a developer of portable brain imaging technology aimed at improving the diagnosis and treatment of traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company designs portable scanners that utilize near-infrared imaging to deliver high-resolution, point-of-care medical imaging. These wearable devices provide critical information throughout the clinical pathway, facilitating automatic analysis and efficient data transfer. By equipping clinicians with rapid and accurate diagnostic tools, Cortirio enhances decision-making processes and improves care for patients suffering from brain injuries and strokes, ultimately aiming to reduce treatment times and prevent long-term disability or death.

Occuity Ltd is a company focused on the research, design, and manufacture of non-contact optical instruments for healthcare diagnostics and monitoring. Established in 2019 and based in Reading, United Kingdom, Occuity develops a range of handheld optical devices, including pachymeters, pupillometers, and keratometers, which are used in both human and veterinary optometry. These instruments function by projecting light into the eye and analyzing the reflected signals, allowing for direct measurements that assist optometrists and ophthalmologists. Additionally, Occuity's technology facilitates the monitoring of various health conditions, such as diabetes and Alzheimer’s disease, thereby enhancing the effectiveness and accessibility of diagnostic and screening tools in healthcare.

AMPLY Discovery is a biotechnology company focused on drug discovery, utilizing machine learning and synthetic biology to explore vast biological datasets for novel drug and nutraceutical candidates. The company operates a proprietary platform that integrates in silico and in vitro approaches to identify first-in-class molecules, addressing significant health challenges such as cancer, metabolic diseases, and multidrug-resistant infections. By digitizing life's natural diversity, AMPLY enhances the predictability and cost-effectiveness of discovering new therapeutics, enabling research entities to identify promising drug candidates based on their functional properties.

PulmoBioMed is a company focused on providing innovative solutions for clinicians and researchers through non-invasive sampling of fluids. The firm has developed a passive fluid aerosol sampler designed to capture exhaled breath condensate and aerosol samples. This product effectively segregates exhaled and environmental particles by size, addressing critical challenges such as sample contamination and loss. PulmoBioMed's technology aims to generate highly reproducible data with precise digital molecular analysis, facilitating the study of biological agents and supporting metabolomic profiling. Through its advancements, the company seeks to enhance research capabilities and improve patient outcomes in the field of respiratory health.

Lucida Medical is a healthcare technology company focused on developing artificial intelligence solutions to enhance the detection and diagnosis of cancer. The company’s flagship product, Pi, is a CE marked medical device that utilizes multiparametric and diffusion MRI to support prostate cancer diagnosis. By leveraging advanced imaging and multi-omics biomarkers, Lucida Medical aims to provide clinicians with accurate, accessible, and cost-effective tools for cancer screening and management. Their innovative technology is designed to improve the efficiency of cancer detection, ultimately enabling healthcare professionals to make timely and informed decisions regarding patient care.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Holly Health is a digital health application designed to assist individuals in translating their health intentions into actionable daily practices for improved mental and physical wellbeing. Utilizing proprietary AI technology, the platform provides a personalized and empathetic experience that simulates the guidance of a human health coach. The application has received high ratings for its effectiveness in weight management, stress reduction, wellness, and sleep, earning a commendable score of 89% from ORCHA, a leading health app evaluation organization. Since its international launch in Summer 2021, Holly Health aims to support 5 million users by 2025 and is expanding its presence through partnerships with primary care practices in the UK, having established over 100 collaborations to date. The app features habit reminders, tailored health content, progress tracking, and motivational support, enabling users to prioritize and maintain healthier habits in their daily lives.

Holly Health is a digital health application designed to assist individuals in translating their health intentions into actionable daily practices for improved mental and physical wellbeing. Utilizing proprietary AI technology, the platform provides a personalized and empathetic experience that simulates the guidance of a human health coach. The application has received high ratings for its effectiveness in weight management, stress reduction, wellness, and sleep, earning a commendable score of 89% from ORCHA, a leading health app evaluation organization. Since its international launch in Summer 2021, Holly Health aims to support 5 million users by 2025 and is expanding its presence through partnerships with primary care practices in the UK, having established over 100 collaborations to date. The app features habit reminders, tailored health content, progress tracking, and motivational support, enabling users to prioritize and maintain healthier habits in their daily lives.

At Holly Health, we are transforming the way individuals approach mental and physical well-being. Founded in 2020, we’ve developed an AI-powered digital health coach that empowers users to turn their health intentions into clear, actionable steps. Our personalized, compassionate service is designed to fit seamlessly into everyday life, supporting long-term, sustainable health changes. Using proprietary AI systems, Holly Health mimics the guidance of a human health coach, offering support in areas such as weight management, stress reduction, wellness, and sleep. We are proud to be ranked among the top 3 health apps by ORCHA, the world’s leading health app evaluation body, with a score of 89%. Since our international launch in 2021, Holly Health has been on a mission to improve the lives of 5 million people by 2025. We are rolling out partnerships with over 100 primary care practices in the UK, helping healthcare professionals support patients with preventative health measures and ongoing well-being. At Holly Health, we believe that health is not a destination but a journey. By offering tailored, science-backed coaching, we make it easier for people to prioritize their well-being every day. Join us as we revolutionize digital health coaching for the modern world.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

ZiO Health is a biotechnology company focused on enhancing patient outcomes through its innovative pocket-sized laboratory testing technology. The company has developed proprietary biosensor devices that utilize machine learning algorithms to provide real-time results tailored to individual patient profiles. These multi-functional electronic devices are designed for measuring, testing, and detecting the molecular composition of various chemical and biological substances, enabling users to assess the presence, absence, or quantity of specific target molecules. By delivering quality home diagnostics and personalized testing solutions, ZiO Health aims to empower individuals to optimize their health and prevent illness.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

Kalium Health Ltd is a medical technology company based in Cambridge, United Kingdom, that specializes in designing and manufacturing innovative tests for blood potassium concentration. Founded in 2018 and previously known as Kalium Diagnostics Ltd, the company focuses on patient-centric approaches to manage kidney disease, which significantly impacts healthcare costs. Kalium Health is developing a user-friendly finger-prick blood test that allows patients to monitor their potassium levels conveniently and affordably, addressing a critical risk associated with kidney disease. This technology aims to provide real-time, clinically actionable health insights into cardiorenal diseases, thereby transforming the standard of care for millions of patients. With a clear regulatory pathway and a targeted go-to-market strategy, Kalium Health is positioned to make a significant impact in the field of kidney care.

genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade'​ business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

SMi Systems is a biomedical research and medical equipment manufacturing organization that specializes in developing advanced discovery and diagnostic tools. Its flagship product, SMi Drug Discovery, is a high-performance diagnostic device capable of detecting diseases within the first 24 hours of infection. This innovative device can simultaneously identify multiple diseases and process numerous patient samples in a matter of minutes. By facilitating the detection of individual disease-associated molecules, SMi Systems' automated and high-throughput diagnostic tools enable scientists to measure critical molecular interactions essential for understanding therapeutic mechanisms. This capability allows researchers to observe a vast diversity of molecular interactions across various disease areas and monitor drug binding to their targets, thereby advancing scientific research and clinical diagnostics.

SMi Systems is a biomedical research and medical equipment manufacturing organization that specializes in developing advanced discovery and diagnostic tools. Its flagship product, SMi Drug Discovery, is a high-performance diagnostic device capable of detecting diseases within the first 24 hours of infection. This innovative device can simultaneously identify multiple diseases and process numerous patient samples in a matter of minutes. By facilitating the detection of individual disease-associated molecules, SMi Systems' automated and high-throughput diagnostic tools enable scientists to measure critical molecular interactions essential for understanding therapeutic mechanisms. This capability allows researchers to observe a vast diversity of molecular interactions across various disease areas and monitor drug binding to their targets, thereby advancing scientific research and clinical diagnostics.

CGT Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. Based in central London with over 120 experts and state-of-the-art laboratories, CGT Catapult offers a comprehensive platform for product development, clinical trials, manufacturing, regulatory support, health economics, and market access expertise. Additionally, they are constructing a £55 million large-scale GMP manufacturing centre to accelerate the delivery of cell and gene therapies to patients worldwide.

Kids Speech Labs is a digital health company focused on transforming the delivery of speech and language therapy services through innovative technology. The company utilizes artificial intelligence to create engaging speech and language games, which facilitate remote monitoring of children's speech development. This approach allows parents to actively track their children's progress in a more interactive and effective manner. By leveraging AI-driven solutions, Kids Speech Labs aims to enhance the accessibility and effectiveness of speech therapy, ultimately supporting better outcomes for children in need of these services.

GG Care helps care residents stay independent and help carers monitor their well-being, comfort, and mood. They serve people with dementia maintain daily routines and stay socially connections shown to reduce cognitive decline and increase happiness and creates an environment to help reduce agitation - significantly reducing the cost of care.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

Tycho Medlink is to help people achieve new levels of rehabilitation through digital therapy.

Nanovery Limited, based in London, United Kingdom, specializes in the development of nanorobots aimed at detecting cancer mutations. Incorporated in 2018, the company leverages advances in nanotechnology, medicinal chemistry, and artificial intelligence to create a platform that enables rapid and sensitive identification of challenging disease biomarkers. These nanorobots are designed to be introduced into blood samples, where they capture circulating tumor DNA and emit a fluorescent signal, facilitating point-of-care detection. This innovative approach not only aids in the early detection of cancer but also enhances the ability to predict the evolution of cancer cells, significantly improving the chances of patient survival. Supported by academic experts, clinicians, and industry leaders, Nanovery is committed to making cancer detection more efficient and accessible.

GenoME Diagnostics is a biotechnology company focused on developing innovative blood tests aimed at improving cancer detection and diagnosis. The company has created the OvaME product, which enhances the traditional CA125 blood tests, offering a more accurate and earlier detection of various cancers. By employing advanced techniques, GenoME Diagnostics aims to minimize misdiagnosis and late detection, enabling healthcare professionals to diagnose and treat patients more effectively. This commitment to developing life-saving diagnostic tools positions the company as a significant player in the field of oncology diagnostics.

Syndi is a digital health support recommendation platform that utilizes machine learning and digital phenotyping, with a primary focus on mental health. The company develops technology-driven solutions aimed at enhancing individuals' health by providing effective and accessible support. Syndi's platform employs passive smartphone data collection to gather moment-to-moment information about users, allowing it to deliver personalized and immediate care. This innovative approach not only facilitates connections between patients and healthcare providers but also measures the effectiveness of applications and digital services in treating invisible disabilities. Through its commitment to leveraging technology and research, Syndi seeks to improve healthcare outcomes for its users.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Healthera's technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.

NIQS Technology is a spin-out from the University of Leeds specializing in innovative quantum glucose management solutions aimed at transforming diabetes care. The company has developed a patented, non-invasive glucose monitoring technology that employs a contact-based wearable device made of nano-engineered glass. This device mimics the optical properties of glucose, allowing for continuous, accurate glucose level monitoring without the need for needles or blood sampling. By providing accessible and user-friendly monitoring solutions, NIQS Technology seeks to empower individuals living with diabetes to manage their condition more effectively and improve their overall quality of life, while minimizing the risk of complications associated with traditional glucose management methods.

Emm is focused on creating advanced consumer health tools that enable individuals to manage their health according to their personal preferences. The company is developing a wearable device specifically designed to enhance reproductive health by providing biometric data. This data offers actionable insights into an individual's unique reproductive profile, allowing users and their healthcare providers to identify potential health issues and improve overall reproductive health outcomes. Emm aims to empower individuals by fostering a deeper understanding of their health through innovative technology and specialized knowledge.

52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.

Vann is a platform for people affected by cancer aiming to help millions of people globally and revolutionize cancer research and care. Vann has been backed by the Oxford University Innovation, Innovate UK, OxLEP European Regional Development Fund, and UK angel investors and is based in the UK.

iEthico is a technology company that specializes in streamlining the sourcing of medicines through its innovative digital platform. The company's automated cloud-based service tracks essential data and provides critical intelligence, alerting users to shortages and connecting them with reliable sources. iEthico's platform is approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and features an automated regulatory process that eliminates paperwork, saving pharmacies significant time and effort. Following successful market testing, iEthico's solution is being rolled out to community pharmacies and NHS Trusts across the UK. The company aims to empower pharmacists by delivering insights that help mitigate the impact of medicine shortages, enabling distributors and providers to navigate multiple suppliers efficiently, reduce costs, and supply medicines across various geographies.

Silveray is a company focused on developing affordable large-area direct conversion detectors specifically for the X-ray imaging market. It leverages advanced core technology that delivers high-performance X-ray imaging through the use of nanoparticle-based X-ray conversion materials. These materials are produced as a semiconductor ink, which is then deposited onto a pixel backplane. This innovative approach enables healthcare providers and various industries to generate an electrical current response to detected X-ray photons, all while maintaining a sustainable cost point. Silveray aims to enhance the efficiency and accessibility of X-ray imaging solutions.

Drill Surgeries is a company dedicated to enhancing the outcomes of trauma and orthopedic surgeries through its innovative AI-powered navigation system. This technology aims to significantly reduce the failure rate of surgeries from 36% to less than 4% by providing real-time guidance during osteosynthesis procedures. By employing proprietary AI algorithms and mixed reality technologies, Drill Surgeries facilitates a remarkable 83% reduction in operating room time. Additionally, the company’s solutions eliminate the need for unnecessary X-rays, leading to substantial cost savings of approximately $2,000 per operation for hospitals. Through these advancements, Drill Surgeries empowers doctors to perform complex procedures more efficiently and effectively, ultimately improving patient care and operational efficiency in healthcare settings.

Acurable Limited is a MedTech company based in London, specializing in the development and commercialization of a wearable sensor-based health care device aimed at diagnosing and managing respiratory conditions. Founded in 2016, Acurable has created the AcuPebble, a device that enables non-invasive diagnosis of sleep apnea and other respiratory issues through the collection and analysis of acoustic signals. The AcuPebble employs advanced algorithms to extract clinically relevant parameters and biomarkers, facilitating automated and accurate diagnosis while significantly reducing the risk of misdiagnosis. This innovative technology, the result of a decade of research at Imperial College London, allows for home use without the need for specialist training or hospital visits, thereby lowering overall healthcare costs. Acurable's mission is to enhance understanding of human biosignals to ensure that no one dies from a treatable condition.

ProtonDx is a diagnostic platform that specializes in molecular testing services, focusing on the rapid and precise detection of multiple pathogens from samples. The company develops point-of-care diagnostic test devices aimed at assisting healthcare professionals in diagnosing infectious diseases. Utilizing innovative microchip technology, ProtonDx integrates molecular biology with machine learning, allowing for swift deployment in clinical settings. This enables healthcare organizations to efficiently manage infected patients and monitor pandemic situations in real-time. ProtonDx emphasizes speed, sensitivity, specificity, and convenience in its offerings, positioning itself as a vital resource for frontline healthcare staff.

AMPLY Discovery is a biotechnology company focused on drug discovery, utilizing machine learning and synthetic biology to explore vast biological datasets for novel drug and nutraceutical candidates. The company operates a proprietary platform that integrates in silico and in vitro approaches to identify first-in-class molecules, addressing significant health challenges such as cancer, metabolic diseases, and multidrug-resistant infections. By digitizing life's natural diversity, AMPLY enhances the predictability and cost-effectiveness of discovering new therapeutics, enabling research entities to identify promising drug candidates based on their functional properties.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Medwise.ai operates a customizable search platform designed to enhance clinical decision support for doctors. Leveraging natural language processing and artificial intelligence, the platform allows healthcare professionals to efficiently search for and organize medical knowledge. By utilizing real-world data, Medwise.ai provides valuable insights and intelligence to various stakeholders within the healthcare ecosystem. This innovative approach not only extends the capabilities of physicians but also aims to improve patient care and outcomes.

GenoME Diagnostics is a biotechnology company focused on developing innovative blood tests aimed at improving cancer detection and diagnosis. The company has created the OvaME product, which enhances the traditional CA125 blood tests, offering a more accurate and earlier detection of various cancers. By employing advanced techniques, GenoME Diagnostics aims to minimize misdiagnosis and late detection, enabling healthcare professionals to diagnose and treat patients more effectively. This commitment to developing life-saving diagnostic tools positions the company as a significant player in the field of oncology diagnostics.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

ChromaTwist is a developer of innovative ultraviolet fluorescent dyes designed for applications in bio-sensing and bio-imaging diagnostic tests. The company's proprietary technology platform utilizes shifted organic fluorescent dyes, which emit visible light upon UV irradiation. These dyes are composed of aromatic organic materials featuring donor and acceptor groups, allowing them to absorb UV light and emit across the full visible spectrum. ChromaTwist's modular and scalable chemistry enables the continuous advancement of their fluorophores, thereby expanding their potential applications in the healthcare sector, particularly in areas like flow cytometry and multiphoton microscopy.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.

Invatech Health provides software as a service solution. It also develops several products to address unresolved issues in areas such as domiciliary care and mental health. It specializes in the healthcare and social care industries.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

Decorte Future Industries is a venture-backed startup focused on developing artificial intelligence technology to extract health data from sound. The company employs advanced machine-learning methods to analyze audio recordings captured by standard microphones, allowing for the extraction of complex biometrics including cardiovascular and respiratory health indicators, among other human health markers. This innovative approach enables clients to gather intricate health data efficiently and at scale, transforming how health information is collected and utilized.

BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

Medwise.ai operates a customizable search platform designed to enhance clinical decision support for doctors. Leveraging natural language processing and artificial intelligence, the platform allows healthcare professionals to efficiently search for and organize medical knowledge. By utilizing real-world data, Medwise.ai provides valuable insights and intelligence to various stakeholders within the healthcare ecosystem. This innovative approach not only extends the capabilities of physicians but also aims to improve patient care and outcomes.

ONKO is a provider of unified cancer care. ONKO combines digital technology with the support of healthcare professionals to provide patients with personalised expertise from cancer dietitians, physiotherapists, specialist nurses and psychologists.

Thomson Screening is a supplier of software for health needs assessments, immunisations, and health screening. They offer schoolscreener software for managing and automating health program requirements. They also provide workscreener platform to provide critical health information to employers across sectors, such as the private sector and the public sector.

Game Doctor develops data-driven gamification technology. They offer services that include big data, mobile applications, health promotion, health marketing, public health, engagement, and behavior change.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

Appt is making preventive healthcare effortless and accessible. Appt uses behavioural economics and data analytics to increase the uptake of preventive healthcare appointments - earning practices additional income and helping the delivery of nationally set prevention targets. Furthermore, through end-to-end automation of the call and recall process, Appt reduces cumbersome practice workload saving practice staff valuable time.

Circada's unique lighting controls improve health and well-being. This consists of an adapter that connects to existing tuneable white LED drivers and is simple to retrofit without the need for complex commissioning, with a standard light switch serving as its interface. We can provide additional configuration prior to installation if necessary for a specific project in order to match the lighting specification, once again providing advanced circadian lighting that is plug-and-play and commission free.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, utilizes advanced molecular methods, including polymerase chain reaction (PCR), to deliver rapid and accurate results. This capability allows clinics and medical professionals to detect infections swiftly and make informed treatment decisions in a decentralized healthcare setting, ultimately improving patient outcomes.

Gendius Ltd. is a company based in Macclesfield, United Kingdom, founded in 2011 by Chris Genders and Rory Cameron. It specializes in developing an app-based platform designed to assist individuals living with diabetes. The company's flagship product, Intellin, leverages a patient's clinical history to identify unique high-risk areas for potential complications related to diabetes. By doing so, Intellin aims to empower users with clinically validated tasks and measures tailored to their specific risks, helping them manage their condition more effectively and reduce the likelihood of complications.

BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.

Echopoint Medical Ltd, established in 2018 and headquartered in London, specializes in developing medical devices that incorporate optical-fibre based sensors. The company leverages optical fibre sensing technologies to enhance precision and efficacy in invasive cardiology and other minimally invasive procedures, with a focus on transforming the diagnosis and treatment of cardiovascular diseases.

Healum is a developer of AI-powered software and applications aimed at enhancing self-management for individuals with long-term health conditions. The company’s technology enables users to effectively monitor and comprehend their physical and mental well-being. By leveraging data-driven insights and evidence-based behavioral interventions, Healum provides personalized care and support tailored to each patient's needs. This approach not only empowers patients in managing their chronic conditions but also aids healthcare professionals in delivering more effective care. Through its innovative solutions, Healum strives to improve health outcomes and promote greater patient engagement in their health management.

Feebris Ltd is a UK-based company, founded in 2017 and headquartered in Saffron Walden, that specializes in developing artificial intelligence and machine learning algorithms for the detection of respiratory conditions. The company creates a mobile software platform that integrates with various point-of-care devices, such as digital stethoscopes and wearables. This technology is designed for community-based diagnosis and monitoring, allowing non-clinical users to identify early signs of deterioration in patients, thereby preventing complications and reducing the need for hospitalization. Feebris' team comprises experts in biomedical engineering, machine learning, global health, and business, all dedicated to transforming healthcare into a more equitable, personalized, and patient-driven system.

CGT Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. Based in central London with over 120 experts and state-of-the-art laboratories, CGT Catapult offers a comprehensive platform for product development, clinical trials, manufacturing, regulatory support, health economics, and market access expertise. Additionally, they are constructing a £55 million large-scale GMP manufacturing centre to accelerate the delivery of cell and gene therapies to patients worldwide.

Concentric Health is a company focused on transforming health decision-making through its innovative e-consent application. The application enhances efficiency by addressing backlog issues and minimizing medico-legal risks through the use of trusted content. It aims to simplify complex processes for both patients and clinicians, fostering shared decision-making that is informed by patient outcomes. By providing a secure and auditable platform, Concentric Health improves the overall experience for users, ultimately leading to better health outcomes.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Mendelian is a company focused on accelerating the diagnosis of rare genetic diseases. It employs advanced machine learning and knowledge reasoning techniques to analyze patients' clinical features, allowing physicians to identify the genes and mutations responsible for various undiagnosed conditions. By utilizing an intelligent agent, Mendelian streamlines the process of matching patients' phenotypic characteristics with potential genetic causes, thereby enhancing the ability of healthcare professionals to diagnose rare diseases more efficiently. This innovative approach aims to improve patient outcomes by enabling earlier detection and treatment of these complex conditions.

MediSieve Ltd. is a London-based medical device company specializing in Magnetic Blood Filtration (MBF) technology aimed at treating blood-borne diseases. Founded in 2014, the company has developed a system that utilizes a magnetic filter to physically remove infected blood cells from a patient's bloodstream. The process involves circulating blood through an external loop where targeted magnetic particles are infused, binding to disease-relevant targets. This filtered blood then passes through a magnetic filter that captures the particles and bound targets, allowing the unaffected blood to return to the patient without the particles entering their body. MediSieve's innovative approach is applicable to various conditions, including malaria, leukaemia, sepsis, and other blood-borne diseases, enhancing the efficacy and safety of existing therapies. The company operates out of the Imperial Incubator in White City, London, where it conducts product development and validation in its dedicated laboratory facilities.

BIOS Health is a pioneering company focused on developing neural digital therapies by harnessing data-driven insights from the human nervous system. Co-founded by researchers from Cambridge University, the firm aims to revolutionize precision medicine through the identification of neural biomarkers that link nerve activity to various medical conditions. BIOS's innovative approach holds promise for treating chronic diseases such as hypertension, diabetes, rheumatoid arthritis, and neurodegenerative disorders like Parkinson's and Alzheimer's. The company's expertise encompasses a diverse range of fields, including neuroscience, machine learning, software engineering, and biotechnology, allowing it to create advanced solutions for improving the quality of life for individuals suffering from these conditions. Additionally, BIOS is engaged in developing prosthetic connectors that standardize the interface between bionic devices and the body's nervous and soft-tissue systems, enabling enhanced control and feedback for patients with prosthetics.

Ieso Digital Health Ltd. is a United Kingdom-based company specializing in online evidence-based mental health therapy. Founded in 2000 and formerly known as PsychologyOnline.co.uk Limited, Ieso provides a platform for one-to-one therapy sessions, allowing patients to engage with accredited therapists in a virtual environment tailored to their schedules. The company addresses a variety of mental health conditions, including anxiety, depression, eating disorders, and relationship issues, as well as chronic physical health problems and cognitive impairments. Utilizing cognitive behavioral therapy (CBT), Ieso employs proprietary technology enhanced by natural language processing and artificial intelligence to facilitate real-time monitoring and improve therapeutic outcomes. Its services cater to a diverse clientele, including health providers, private individuals, and businesses, aiming to transform the landscape of mental healthcare through scalable digital products and therapeutics.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, that specializes in developing innovative antibiotics to combat antibacterial resistance. The company utilizes its proprietary SASPject platform, which employs small acid-soluble spore proteins delivered via targetable non-delivery vehicles to specific bacterial strains. Its product portfolio includes SASPject PT3, designed to target Pseudomonas aeruginosa; SASPject PT4 and PT5, which are aimed at Klebsiella pneumonia and Escherichia coli, respectively; and SASPject PT1.2, focused on Staphylococcus aureus. Additionally, Phico Therapeutics is working on an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses in conjunction with antibacterial proteins to inhibit bacterial growth and toxin release. Founded in 2000, the company is dedicated to addressing critical challenges in antibiotic resistance through its advanced therapeutic approaches.

Mayden House is a technology company that specializes in developing cloud-based software solutions for the healthcare sector. The company focuses on creating end-to-end managed web applications and bespoke system development, offering services that include patient management, operational management, digital care record systems, and analytics. Mayden House aims to enhance healthcare delivery by providing innovative and flexible technology that supports data-driven, outcome-focused, and patient-centered care. With a commitment to adding real value to healthcare, the company operates from two locations between Bath and Chippenham and employs 44 staff, supported by a network of skilled associates for project-based work.

Vitamica Ltd is a diagnostic technology company based in Bristol, United Kingdom, founded in 2018 as a spin-out from the University of Bristol. The company specializes in rapid antimicrobial susceptibility testing (AST) that enables the swift identification of pathogenic bacteria and their resistance to antibiotics. By utilizing advanced optical technology, Vitamica's innovative approach detects nanoscale fluctuations in live bacteria, providing clinicians with critical information to guide antibiotic treatment decisions. With a growing portfolio of intellectual property, Vitamica aims to make significant contributions to the healthcare, veterinary, and pharmaceutical sectors through its novel diagnostic methods.

PulmonIR is a medical technology company focused on developing innovative devices for the early detection and continuous monitoring of chronic obstructive pulmonary disease (COPD) and other lung diseases. Their products aim to improve diagnostic efficiency for healthcare professionals, ensuring timely and effective treatment for patients suffering from these conditions.

Accurx is a healthcare communication platform that facilitates seamless interaction between patients and healthcare professionals. The platform allows users to send SMS messages, administer medical surveys, issue appointment reminders, and manage referrals. It also supports video consultations and the oversight of virtual wards, outpatient clinics, and follow-up pathways. Accurx is widely adopted, utilized by 98% of GP practices and over 50% of NHS trusts, thereby enhancing efficiency in primary care and improving patient engagement. The company's tools are designed to simplify and streamline communication, making it easier for medical professionals to connect with their patients effectively.

Eagle Genomics is an enterprise software solutions company specializing in the management and analysis of genomics and life sciences data. Its innovative platform facilitates the curation, integration, sharing, and analysis of scientific data, thereby enhancing productivity and reducing costs and time in research and development. By transforming data sets into valuable assets, the company redefines how digital information is measured and utilized, providing insights into the return on information. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics addresses the challenges faced by industries such as pharmaceuticals, consumer goods, and agri-tech, particularly in managing the increasing volume of data. The company is positioned at the forefront of delivering the essential information architecture needed for the genomics era, helping clients navigate the complexities of data-driven research and development.

Andiamo is a custom medical wearables platform that focuses on providing innovative solutions for neuromuscular conditions, beginning with cerebral palsy. The company operates a digital clinic that connects families with specialists, ensuring they receive the necessary care and expertise when and where it is needed. By leveraging technology, Andiamo aims to improve the quality of life for individuals with neuromuscular disorders through tailored wearable devices and specialized medical services.

MyWay Digital Health is an online self-management platform focused on enhancing the lives of individuals with long-term health conditions, particularly diabetes. The platform offers users access to their health records, personalized advice, and educational resources aimed at empowering them to manage their conditions effectively. Additionally, it provides clinical and management tools that support population analytics and clinician decision-making. Through its data-driven technology solutions, MyWay Digital Health seeks to improve health outcomes for users worldwide by facilitating better management of their health conditions.

Miotify Ltd. is a company that specializes in developing software and online toolkits aimed at enhancing the quality of digital health applications. Founded in 2015 and based in Windsor, United Kingdom, Miotify's system is designed to empower both developers and non-IT personnel to create applications within a structured framework, ensuring quality is integrated from the outset. The software facilitates the auto-generation of evidence for regulatory submissions while transforming data from devices and sensors for remote patient monitoring in clinical trials. Additionally, Miotify's solutions provide medical practitioners and researchers with tools for iterations tracking, lifecycle management, and the analysis of clinical data. This enables healthcare professionals to make informed clinical decisions and gather insights that significantly improve patient care.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

Activirosomes is a biotechnology company focused on the development of innovative vaccines and virotherapies designed to combat viral infections. Utilizing an active virosome technology, the company creates multivalent vaccines that target various health challenges, including cancer and infectious diseases such as avian and Zika viruses. Activirosomes is committed to producing effective, safe, and affordable solutions that address both existing and emerging viral threats, aiming to improve public health outcomes through its advanced therapeutic approaches.